March 26, 2018 / 12:22 PM / 8 months ago

BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide

1 Min Read

March 26 (Reuters) - Amag Pharmaceuticals Inc:

* AMAG PHARMACEUTICALS SUBMITS A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR BREMELANOTIDE FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below